![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”...
SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was...
Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que des membres de son équipe de direction, parmi lesquels Hervé...
Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate’s second generation ANKET®, for the treatment...
Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce les résultats du vote des actionnaires à l’Assemblée générale mixte qui s’est tenue...
Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui qu’un abstract publié le 14 mai 2024 en amont du congrès de...
By Dean Seal Innate Pharma's American depositary receipts rose after the company said Sanofi had exercised its option to license a natural killer cell engager program in solid tumors from...
By Colin Kellaher Shares of Innate Pharma dropped in premarket trading Thursday after the biopharmaceutical company said the U.S. Food and Drug Administration placed a partial hold on studies of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.015 | 0.722891566265 | 2.075 | 2.13 | 2.005 | 23324 | 2.05266762 | DE |
4 | 0.04 | 1.9512195122 | 2.05 | 2.13 | 1.862 | 46813 | 1.99874886 | DE |
12 | -0.165 | -7.31707317073 | 2.255 | 2.79 | 1.862 | 74824 | 2.34746469 | DE |
26 | -0.36 | -14.693877551 | 2.45 | 2.79 | 1.862 | 69356 | 2.31772186 | DE |
52 | -0.825 | -28.3018867925 | 2.915 | 3.04 | 1.862 | 87137 | 2.42094718 | DE |
156 | -0.61 | -22.5925925926 | 2.7 | 5.735 | 1.862 | 195600 | 3.42065849 | DE |
260 | -3.63 | -63.4615384615 | 5.72 | 7.5 | 1.862 | 264244 | 4.10928321 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions